A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures.

Trial Profile

A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2018

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Seizures; Tuberous sclerosis
  • Focus Registrational; Therapeutic Use
  • Sponsors GW Pharmaceuticals; GW Research
  • Most Recent Events

    • 27 Feb 2018 Based on the results of this trial, the Company expects to submit regulatory applications in 2019 for Epidiolex in Tuberous Sclerosis in both the U.S. and Europe, according to a GW Pharmaceuticals media release.
    • 05 Feb 2018 According to a GW Pharmaceuticals media release, data from this trial is expected in H2 2018.
    • 20 Oct 2017 Planned number of patients changed from 192 to 210.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top